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Elevated levels of circulating immune complexes (CIC), containing IgG, IgM or IgA antibodies were
detected in the sera of patients with autoimmune diseases. This might indicate a different biological
meaning of the three isotypes of immunoglobulin (Ig) in the CIC. Each CIC assay detected only certain
classes and subclasses of Ig in CIC material or ﬁxed complement protein. In this study, a new method
based on C3binding glycoprotein named CIF-ELISA and awell-known method ANTI-C3 ELISA, were
used for quantitative assessment of IgM-CIC, IgG-CIC and IgA-CIC levels in human sera. A modiﬁed
CIF-ELISA and ANTI-C3 ELISA for simultaneous detection of CIC, containing IgG, IgM and IgA,
(stCIC), were also performed. The assays were evaluated on the same specially prepared samples: 55
normal sera, 99 sera from rheumatoid arthritis (RA), 88 sera from systemic lupus erythematosus (SLE),
and 27 sera from progressive systemic sclerosis (PSS). We found that the sensitivity of the tests used
varied depending on the diseases studied. CIF-ELISA displayed higher sensitivity of IgM-CIC when
compared to ANTI-C3 ELISA in RA patients (40.0 and 20.95%, respectively) and PSS (44.43 and
37.04%, respectively). Results for the sensitivity of IgA-CIC were in adverse direction in the RA group
(14.28 and 19.05%) and PSS (14.81 and 25.93%) by both methods. It was also established that the
concordance of IgM-CIC positives by both methods was 48.84% in RA and 46.67% in PSS, while in
SLE it was 18.78%. These results are most probably due to the different assay abilities to detect
antibody isotype of the CIC material and help to explain what speciﬁc role each Ig isotype in CIC has in
the course of the disease.
Keywords: ANTI-C3 ELISA; CIF-ELISA; C3bgp; Immune complex detection; Immune complex
diseases
Abbreviations: AU, arbitrary unit; CIC, circulating immune complexes; CIF, C3 binding glycoprotein
isolated from Cuscuta europea seeds; IgA-CIC, circulating immune complexes, containing IgA; IgM-
CIC, circulating immune complexes, containing IgM; IC, immune complexes; PSS, progressive
systemic sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; stCIC, CIC levels,
detected by the screening test
INTRODUCTION
The importance of the immune complexes (IC) as a trigger
of many autoimmune diseases is well established
(Theoﬁlopoulos and Dixon, 1980; Westedt et al., 1986;
Edwards and Cambridge, 1998). In the same time the
dependency between the serum levels of the circulating
immune complexes (CIC) and the disease activity is not
yet completely elucidated (Ruddy and Moxley, 1994).
One of the reasons for this problem may be related to the
characteristics of the materials detected (McDougal et al.,
1982). It is well known that most of the tests used for
quantitative assessment of CIC can detect preferentially
IC, containing IgG (IgG-CIC). Therefore, the levels of
CIC, containing other immunoglobulin isotypes (mainly
IgM and IgA) will be undetected and the results
obtained—uncompleted. On the other hand, the problem
concerning the quantitative assessment of IgM-CIC and
IgA-CIC is actual because of the currently established data
for the elevated levels of these isotypes CIC in diseases as
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), progressive systemic sclerosis (PSS), IgA nephro-
pathy, vasculitis and other (Iida et al., 1987; Miyazaki,
1990; Jarvis et al., 1992; Jarvis et al., 1995; Kashem et al.,
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1998). All of the mentioned problems suggest that the
usefulness of the tests for parallel detection of CIC,
according different immunoglobulin isotypes contained
will be more appropriate as a tool to better ﬁnd out the
diagnosis and prognosis of a diseases studied.
At present ANTI-C3 ELISA and the conglutinin test are
themostusedantigen-nonspeciﬁcassaysabletodetectCIC
according tothe immunoglobulinisotypes contained (IgG-
CIC, IgM-CIC and IgA-CIC) (Iida et al., 1987; Ruddy and
Moxley, 1994; Lock and Unsworth, 2000). Unfortunately,
both tests can detect false positive results (Aguado et al.,
1985; Holmskov et al., 1992). It is obvious that a new
sensitive and easy performing test for quantitative
assessment of IgM-CIC and IgA-CIC would be actual. In
our previous work, we reported developing of CIF-ELISA
test for quantitative determination of IgG-CIC (Stanilova
and Slavov, 2001). The following studies reveal that this
test could be used for detection of IgM-CIC and IgA-CIC.
In this study we have made and analyze quantitative
assessment of the IgM-CIC, IgG-CIC and IgA-CIC results
obtained by CIF-ELISA and ANTI-C3 ELISA in patients
with RA, SLE and PSS.
MATERIALS AND METHODS
Collection and Storage of Samples
All samples were routinely processed within 4h of
collection. Blood samples were obtained from 214
patients of the three diseases: RA—99, SLE—88, and
PSS—27 as well as 55 healthy adults volunteers for
investigation. The patients were selected without acces-
sory illnesses, according to the American College of
Rheumatology criteria, as models of typical autoimmune
diseases (Masi et al., 1980; Tan et al., 1982; Arnett et al.,
1988). The healthy HIV and HBsAg negative individuals
were selected from Haemotransfusion center Stara Zagora
blood donors. Serum samples from the patients and
healthy adults were separated at room temperature (RT),
and stored at 2208C until use.
Assay System
CIF-ELISA
CIF-ELISA was performed according to the protocol,
described previously with modiﬁcations (Stanilova and
Slavov, 2001). Flat bottom polystyrene microtitter plates
were coated with 20mg/ml CIF in 0.2M carbonate–
bicarbonate buffer, pH 9.6 and incubated overnight at 48C.
After washing with 50mM Tris–HCl, pH 7.2, containing
0.05% Tween 20 (2 £ 5min), the plates were blocked for
20min with the same buffer. A measure of 100ml of each
tested serum, diluted 1:50 in sample buffer (0.1M PBS,
containing 1% BSA, 0.2%Tween 20, 1mM CaCl2 and
MgCl2) was added in duplicate and incubated for 60min
at RT. After three washes, 100ml of the appropriate
anti-human immunoglobulin antibodies peroxidase con-
jugate were added to each well as follow:
- Goat anti-human IgM (m-chain speciﬁc) antibodies
peroxidase conjugate diluted 1:15000 in washing
buffer, for detection of IgM-CIC.
- Goat anti-human IgA (a-chain speciﬁc) antibodies
peroxidase conjugate diluted 1:10000 in washing
buffer, for detection of IgA-CIC.
- Goat anti-human IgG (g-chain speciﬁc) antibodies
peroxidase conjugate diluted 1:10000 in washing
buffer, for detection of IgG-CIC.
- Polyvalent goat anti-human IgG,A,M (g,a and m-
chain speciﬁc) antibodies peroxidase conjugate diluted
1:20000 in washing buffer, for simultaneous detection
of IgG-CIC, IgM-CIC and IgA-CIC, named screening
sCIF-ELISA.
All immunoconjugates were incubated for 60min at RT.
After the washing procedure, 100ml of the substrate
solution was added to each well and incubated for 10min
at RT. The developed colour reaction was stopped with
10% H2SO4, and OD units at 492nm were measured on an
ELISA plate reader (Rosys Anthos 2010, Austria).
ANTI-C3 ELISA
It was performed as described by Pereira et al. (1980) with
slight modiﬁcation. In brief, the microtiter plates were
incubated overnight at 48C with 10mg/ml monospeciﬁc
goat IgG antibodies against human C3 component of
complement, diluted in carbonate–bicarbonate buffer,
pH 9.6. After washing procedure (2 £ 5min) and blocking
the unreacted sites (for 20min), the wells were incubated
with 100ml of the tested sera diluted 1:50 in 0.1M PBS,
containing 1%BSA and 0.2% Tween 20 for 60min at RT.
Following 3 washes (3 £ 5min) goat anti-human IgM
(m-chain speciﬁc) conjugate diluted 1:15000 in washing
buffer;orgoatanti-humanIgG(g-chainspeciﬁc)conjugate
diluted 1:10000 in washing buffer; or goat anti-human IgA
(a-chain speciﬁc) conjugate diluted 1:10000 in the same
buffer;orpolyvalentgoatanti-humanIgG,A,M(g,aandm-
chainspeciﬁc)conjugatediluted1:20000inwashingbuffer
were added toeach well.Eachconjugatewas incubated for
60min at RT. The developed colour reaction was stopped
with 10% H2SO4, and OD units at 492nm were measured
on an ELISA plate reader (Rosys Anthos 2010, Austria).
Running the Samples
All sera were tested in parallel for quantitative assessment
of IgG-CIC, IgM-CIC, IgA-CIC and stCIC, by both assays
used. Each serum was tested in duplicate according to
performance characteristics of the tests used, and the
results obtained in OD units were calculated as percent of
positive controls (arbitrary units—AU). The sera shown
OD value higher than X ^ 2SD was used as positive
controls.
S.A. STANILOVA AND E.S. SLAVOV 112Special Reagents and Puriﬁed Proteins
The C3 binding glycoprotein (CIF) was isolated from the
C. europea seeds as described previously (Zhelev et al.,
1994). Sigma purchased goat anti-human C3 antibodies;
goat anti-human IgM-peroxidase conjugate; goat anti-
human IgG peroxidase conjugate; goat anti-human IgA-
peroxidase conjugate, polyvalent goat-anti human
IgG,A,Mperoxidaseconjugateandallreagentsforbuffers.
Statistical analysis was made by Student’s criteria,
Dispersion analysis (F-test), x
2-test and Spearman
correlation analysis.
RESULTS
IgM-CIC Quantitative Assessment in Patients’ and
Healthy Blood Donors’ Sera
The serum levels of IgM-CIC, detected in the group of the
healthyadultvolunteerswereusedtodeterminethenormal
values of this isotype CIC in the healthy population. The
results obtained by CIF-ELISA and ANTI-C3 ELISA
allows us to calculate the normal range X ^ 2SD of IgM-
CIC, which represented that over 95% of test results with
normal sera were negative (speciﬁcity) for both methods
used. The simultaneously tested panel of patients’ sera
with the control group was used to choose the suitable
positivecontrols(higherCIC levelsera)foreach assayand
to calculate AU as percent of positive control (Table I).
Test results obtained for the control and patient
groups are shown in Fig. 1. It was established that the
IgM-CIC levels, detected in the patient groups’ were
signiﬁcantly higher than the control ones ðp , 0;05Þ
for both methods used. F-test, which tested whether the
ratio of the two variances estimated was signiﬁcantly
greater, veriﬁed that there were signiﬁcant differences
between the data of the control and all patients groups
obtained by each of the assays. The greatest F-value
was obtained for CIF-ELISA compared to the ANTI-C3
ELISA in all disease groups studied. That trend was
most evident for PSS group, where F-value were 50.09
for CIF-ELISA and F ¼ 25:11 for ANTI-C3 ELISA.
For the RA group estimated F were 47.87 for
CIF-ELISA and F ¼ 7:72 for ANTI-C3 ELISA.
Only for SLE group the F-values were nearly equal
(F ¼ 23:71 and 22.46, respectively).
Correlation coefﬁcient (r), between the results from the
two of the assays revealed a well-expressed correlation
TABLE I Meanvalue (X), standard deviation (SD) and range (X ^ 2SD) of IgM-CIC and IgA-CICdetected for control group of healthy blood samples
by CIF-ELISA, ANTI-C3 ELISA, and for total CIC levels by screening CIF-ELISA, ANTI-C3 ELISA
IgM-CIC levels IgA-CIC levels CIC levels (by screening tests)
ASSAYS X SD X ^ 2SD X SD X ^ 2SD X SD X ^ 2SD
CIF-ELISA 51.15 18.71 13.73 4 88.57 14.76 9.98 0 4 34.72 51.70 14.09 23.52 4 79.88
ANTI-C3 ELISA 32.38 15.54 1.3 4 63.46 29.63 20.17 0 4 69.97 67.09 10.69 45.71 4 88.74
The results are expressed as percent of positive control—AU.
FIGURE 1 Mean and standard deviation values of IgM containing CIC and IgA containing CIC in control and patient groups detected by CIF-ELISA
and ANTI-C3 ELISA. The data are presented in AU. With * and ** are presented statistically signiﬁcant differences (p , 0.05, and p , 0.01,
respectively) between control and patient groups. C- control group; T - total.
NEW ELISA KITS USING C3 BINDING 113between the IgM-CIC levels, for RA (r ¼ 0:53; p , 0:01)
andPSS(r ¼ 0:50;p , 0:01)groups.Thesameanalysisof
IgM-CIC data for SLE group revealed a slight,
not statistically signiﬁcant correlation (r ¼ 0:01;
p . 0:05).
The relative sensitivity of the assays used, was
calculated as the number of patient sera with positive
results divided to the number of patient sera tested and was
presented as percent in Fig. 2. It was found that the relative
sensitivity varied depending on the diseases studied.
The relative sensitivity was higher by CIF-ELISA
compared to ANTI-C3 ELISA for RA (40.0 and 20.95%,
respectively) and PSS (44.43 and 37.04%) samples,
whereas it was almost equal for SLE (22.73 and 20.45%).
For determining the degree of the coincidence between
the two assays we calculated:
%Concordance¼
100£No:ofanti C3þ=CIFþ
ðNo:ofanti C3þþNo:ofCIFþÞ2No:ofanti C3þ=CIFþ
(i.e. the number of double positives as a percen-
tage of the total number of single and double positive
samples).
This concordance of IgM-CIC positivesera was 48.84%
for RA, 46.67% for PSS and 18.78% for SLE patients as
shown in Fig. 2.
Quantitative Assessment of IgA-CIC in Patients’ and
Healthy Blood Donors’ Sera
The normal range of IgA-CIC levels was estimated upon
the IgA-CIC levels detected from 55 healthy blood
donor sera, and calculated as described for IgM-CIC
(Table I).
The mean values of all patients’ groups, detected by
CIF-ELISA and ANTI-C3 ELISA were higher than the
controls, however, statistically signiﬁcant increased of
IgA-CIC compared to the controls were detected for
SLE group (p , 0:01; by both methods) alone, as
shown in Fig. 1.
F-values calculated for ANTI-C3 ELISA in RA ðF ¼
5:49Þ and SLE ðF ¼ 8:0Þ groups were higher than the
F-values for CIF-ELISA in the same groups (F ¼ 2:38
and F ¼ 7:31, respectively). The F-values, detected for
CIF-ELISA and ANTI-C3 ELISA in PSS group were
nearly equal (F ¼ 2:37 and F ¼ 1:38, respectively),
showing a statistically insigniﬁcant increase of IgA-CIC
in this patients’ group.
The correlation analysis established a well expressed
correlation between CIF-ELISA and ANTI-C3 ELISA
data of IgA-CIC levels for RA (r ¼ 0:34; p , 0:01)
and PSS (r ¼ 0:62; p , 0:01) groups. This analysis
also showed a weak, not signiﬁcant correlation between
the two tests for SLE group (r ¼ 0:07; p . 0:05).
The relative sensitivity for IgA-CIC assessment was
presented in Fig. 2. It was higher by ANTI-C3 ELISA
compared to CIF-ELISA for RA (19.0 and 14.3%,
respectively) and PSS (25.93 and 14.81%) samples,
whereas it was almost equal for SLE (20.45 and 22.73%).
The concordance of IgA-CIC positive sera was 25.0%
for RA group, 22.2% for PSS and 26.7% for SLE patient
group as shown in Fig. 2.
Quantitative Assessment of CIC in Patients’ and
Healthy Blood Donors’ Sera by the Screening
CIF-ELISA and ANTI-C3 ELISA
The CIC values of 55 healthy blood donor sera, detected
by the screening CIF-ELISA (sCIF-ELISA) and screening
ANTI-C3 ELISA (sANTI-C3 ELISA) were used to deﬁne
FIGURE 2 The Relative sensitivity and Concordance of IgG-CIC, IgM-CIC and IgA-CIC positive sera in patient groups detected by CIF-ELISA and
ANTI-C3 ELISA. Relative sensitivity is calculated as percent (%) of positive sera. Concordance is calculated by the formula: the number of double
positives as a percentage of the total number of single and double positive samples.
S.A. STANILOVA AND E.S. SLAVOV 114the normal range of stCIC in the healthy population and
the results are shown in Table I. The stCIC levels detected
in patients’ group were signiﬁcantly higher than the
control ones, by both methods ðp , 0:01Þ.
F-values detected by sCIF-ELISA were higher than
those detected by sANTI-C3 ELISA. For the patients
groups the results were as follow: for RA—F ¼ 50:79 by
sCIF-ELISA and F ¼ 29:28 by sANTI-C3 ELISA, for
SLE—F ¼ 28:84 and F ¼ 6:97 and for PSS—F ¼ 47:81
and F ¼ 4:85, respectively. A well-expressed correlation
between sCIF-ELISA and sANTI-C3 ELISA stCIC levels
for RA (r ¼ 0:35; p , 0:01), SLE (r ¼ 0:36; p , 0:05)
and PSS (r ¼ 0:36; p , 0:05) groups was observed.
The relative sensitivity of sCIF-ELISA and sANTI-C3
ELISA assessment of stCIC, are shown in Fig. 3. It was
higher by CIF-ELISA for RA and PSS groups, while for
SLE group the stCIC positives, detected by both methods
are nearly equal. The concordance of stCIC positive
sera was 43.9% for RA group, 40.97% for PSS
group and 34.78% for SLE serum samples as shown
in Fig. 3.
Distribution of the CIC Positives Sera, Depends on the
Immunoglobulin Isotype Contained
It was also investigated the percent of the distribution of
IgM-CIC, IgA-CIC and IgG-CIC in the sera studied.
The results obtained are presented in Table II. Both
methods used demonstrate three different groups of
positive sera. The ﬁrst one was positive by a single isotype
CIC, the second one was simultaneously positive sera by
two isotypes CIC, followed by a third group with
simultaneously positive sera by all three isotypes CIC. We
established that the positive sera by one isotype CIC
predominated over positive sera, contained two isotypes
CIC simultaneously while triple positives (IgG, IgM and
IgA-CIC) was the least part. When was used CIF-ELISA
the highest percent of IgM-CIC positive sera were
detected, while by ANTI-C3 ELISA the highest percent
of sera were IgA-CIC positive.
FIGURE 3 The Relative sensitivity and Concordance of total CIC
(stCIC) positive sera in patient groups detected by CIF-ELISA and
ANTI-C3 ELISA. The relative sensitivity and concordance are calculated
as in Fig. 2.
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The quantitative assessment of CIC could be made
according to the immunoglobulin isotypes or antigen
contained by CIC (Theoﬁlopoulos and Dixon, 1980;
Nezlin et al., 1998). In this regard the choice of method for
quantitative assessment of CIC might be very important to
better establish the diagnosis, as well as conduct a precise
survey of the disease stage and the course of the treatment
used (Nydegger and Svehag, 1984; Reeback et al., 1985;
Svendsen et al., 1995; Ahmed et al., 1999). In our
previous work, we reported a new quantitative method
named CIF-ELISA as an appropriate method for IgG-CIC
detection (Stanilova and Slavov, 2001). The following
experiments revealed the ability of CIF-ELISA to detect
CIC, containing different immunoglobulin isotypes.
In this study, IgM-CIC and IgA-CIC quantitative
assessment results by CIF-ELISA were compared to
those by well-known ANTI-C3 ELISA method.
The panel of healthy blood donor sera tested by CIF-
ELISA was used to determine the normal range of IgM-
CIC, IgA-CIC and stCIC level. We found that more than
95% of the healthy blood donor sera studied were with
normal levels of these isotypes CIC. The same isotypes
CIC quantity, detected in patients’ groups by CIF-ELISA
were signiﬁcantly higher than the control. These results
allowed us to conclude that CIF-ELISA is able to
distinguish the human sera with elevated IgM-CIC, IgA-
CIC and stCIC levels from the normal ones.
Results obtained strongly suggest that Immunoglobulin
isotypes distribution included in CIC composition from
each patients group was different, which inﬂuenced the
assay sensitivity. It was also supported by the fact that the
percent of positive sera for both assay used calculated as
% concordance was varied depending of IgG or IgM or
IgA-CIC detection. The higher sensitivity of CIF-ELISA
compared to ANTI-C3 ELISA toward IgG-CIC and IgA-
CIC levels was shown for patients with SLE alone. Forthis
patients group the higher concordance between two assays
was established as well regarding IgG and IgA-CIC.
The presence of elevated levels of IgA-CIC in the
pathogenesis of many autoimmune diseases is well
established. They are related with the outcome of the
erosive arthritis and vasculitis (Westedt et al., 1986;
Roccatello et al., 1993; Danning et al., 1998). We detected
elevation in IgA-CIC levels by CIF-ELISA and ANTI-C3
ELISA, with a bit higher sensitivity of the ANTI-C3
ELISA in RA and PSS patients.
The higher sensitivity of CIF-ELISA compared to
ANTI-C3 ELISA toward IgM-CIC levels has been
demonstrated for patients with RA and PSS, but not for
SLE.TheseresultsrevealedthatthequantityofIgM-CICin
patient sera depends on the disease and it is higher in RA
compared to SLE. It is possible that the detected IgM-CIC
in RA patient represents complexes of modiﬁed IgG
antibodies and rheumatoid factors of monomeric IgM
isotype, directed against them. The role of this
immune complex type is considered by some authors
(Ng et al., 1988; Jarvis et al., 1992; Ligier et al., 1998).
Another reason for IgM-CIC persisting in patients sera
might be some disturbances in class switching, leading to
elevation in IgM antibody production (Fedyk et al., 1994).
FurtherstudyisneededtoclarifytheroleofIgM-CICinthe
pathogenesis of the autoimmune diseases, as well as the
role of IgM-CIC as a marker of disease activity, for which
CIF-ELISA methods could be useful. One possible
explanationforthedataobtainedisthefactthatmonomeric
IgM hampers the C3 complement component ﬁxation to
CIC, and these immune complexes remain undetected by
ANTI-C3 ELISA (Balestrieri et al., 1984). Our previously
reported results demonstrated that CIF might binds to
immune complex, regardless of C3 ﬁxing (Stanilova et al.,
1999;Slavovetal.,2000).Wesupposesomeadvantagesof
CIF-ELISA as a method for quantitative assessment of
IgM-CIC in sera of patients, particularly for RA disease.
Our results conﬁrm the indispensability of the
quantitative assessment of IgM-CIC, IgG-CIC and IgA-
CIC in the autoimmune disease patient’s sera. When the
results obtained for IgM-CIC, IgG-CIC and IgA-CIC were
analyzed in parallel, it became clear that some sera
contained simultaneously elevated levels of both isotypes
CIC. This trend was evident by CIF-ELISA as well as by
ANTI-C3 ELISA. We found sera with simultaneously
elevated IgG-CIC, IgM-CIC and IgA-CIC, sera with
elevated levels of two isotypes CIC in different com-
bination-IgG-CICandIgM-CIC;IgG-CICandIgA-CICor
IgM-CIC and IgA–CIC, as well as sera with elevated only
one isotype CIC (IgG-CIC, IgM-CIC or IgA-CIC).
More precise analysis of the results obtained show that
the percent of sera with elevated levels of only one isotype
CIC or of different combination of the three isotypes CIC
studied vary depending on the diagnosis. We found that in
RA and PSS groups mainly persists IgM-CIC, while in
SLE prevails IgG and IgA-CIC.
The data obtained suggest that only the parallel
detection of the three main isotypes CIC could present a
complete information about CIC quantity persisting in
the serum. Unfortunately, at present the only way to
detect these three isotypes CIC is to run in parallel three
ELISA tests, detecting separately IgM-CIC, IgA-CIC
and IgG-CIC. This diagnostic procedure is difﬁcult to be
performed, and its possibilities are limited. In this regard
the development of a screening test, detecting simul-
taneously IgM-CIC, IgA-CIC and IgG-CIC is more
valuable. In the existing literature we did not found data
about the ELISA tests for screening detection of CIC,
regardless of antibody isotypes. We developed modiﬁed
ANTI-C3 ELISA and CIF-ELISA screening tests, using
the polyvalent IgG, IgM and IgA immunoconjugate as a
detecting antibody. Our results demonstrated a well-
expressed capacity of screening tests for CIC. That
detection is a simple and quick test for the diagnostic
practice. The higher % of CIC positives detected by
sCIF-ELISA compared to sANTI-C3 ELISA as well as
the higher level of CIC positives simultaneously by both
assays used, allowed us to conclude that sCIF-ELISA is
S.A. STANILOVA AND E.S. SLAVOV 116more appropriate than sANTI-C3 ELISA for quantitative
assessment of total stCIC level.
The ability of CIF-ELISA to detect IgM-CIC, IgA-CIC
and IgG-CIC as well as to detect the total CIC level
might transform it in an useful tool for the routine
laboratory use.
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